Ireland’s cancer clinical trials generated major savings for the State while giving hundreds of patients access to potentially important treatments. New figures show that 230 patients received care through a sample of trials that helped avoid more than €6.5 million in treatment costs over 12 months.
Key findings from the latest Ireland cancer trials report
The figures come from Cancer Trials Ireland’s Value of Cancer Trials 2 report, which examined 38 cancer clinical trials accessed during the year from September 1st, 2025, to August 31st, 2026.
Across the wider clinical research programme, 3,938 patients took part in cancer trials during the same period. Of those participants, 423 were enrolled in drug trials.
- €6.5 million: approximate treatment costs saved by the State through the 38-trial sample.
- 230 patients: accessed treatment through those trials.
- €6.76 million: inward investment generated by pharmaceutical companies through 20 trials.
- 3,938 patients: participated in cancer trials during the 12-month period.
- 423 patients: took part in drug trials.
The results place clinical research at the centre of both cancer care and Ireland’s health economy. Trials can provide eligible patients with access to new therapies while also attracting commercial investment and reducing the cost of some treatments funded through the public health system.
Follow DailyDigest for continuing Health News Ireland and Public Services Ireland coverage.
Why clinical trials matter to patients
Clinical trials are structured studies used to assess medicines, treatment combinations, procedures or care approaches. Cancer trials may focus on preventing disease, detecting it earlier, controlling its progression or improving outcomes and quality of life.
For patients, participation can mean access to a treatment that is not yet routinely available. However, entry is not automatic. Each study has eligibility criteria based on factors such as cancer type, stage, previous treatment, general health and the scientific purpose of the trial.
Patients considering a trial should discuss the option with their oncology team. Healthcare professionals can explain:
- what treatment is being tested;
- the known and possible risks;
- how the trial compares with standard care;
- the appointments, tests and monitoring involved;
- what happens if a participant withdraws or the trial ends.
Participation is voluntary, and informed consent is required before a patient joins a study.
Investment and value for Ireland’s health system
The report also found that 20 trials generated €6.76 million in inward investment from pharmaceutical companies. This funding supports research activity and can strengthen Ireland’s position as a location for international life-sciences development.
Clinical research requires specialist staff, laboratory services, data management, pharmacy support and careful oversight. Investment linked to trials can therefore benefit hospitals and research networks beyond the individual study.
The reported savings should also be understood in context. A clinical trial is not simply a way to remove a treatment bill. It involves dedicated infrastructure, regulatory review and ongoing monitoring. The value comes from the combination of patient access, evidence generation, research capacity and contributions from trial sponsors.
What the figures mean for cancer care
The scale of participation suggests that clinical research is becoming an increasingly important part of cancer services in Ireland. Nearly 4,000 patients took part in cancer trials during the reporting period, although the source figures do not indicate that every participant received a drug treatment.
The distinction matters because cancer research includes more than pharmaceutical studies. Some trials examine surgery, radiotherapy, diagnostic methods, supportive care or other approaches. Drug trials are one part of a broader research system.
For the health service, strong trial activity can help Ireland:
- offer patients more treatment options where they meet study criteria;
- build expertise among clinical and research teams;
- collect evidence relevant to cancer care;
- attract investment from international companies;
- reduce some treatment costs when trial sponsors provide medicines or related support.
What happens next?
The figures are likely to increase attention on the role of Cancer Trials Ireland and the wider clinical research infrastructure. Continued participation will depend on patients being identified early, trials being available across suitable hospitals and research teams having the resources to run studies safely.
Anyone seeking information should begin with their consultant, oncology nurse or hospital research team. Trial availability changes over time, and only authorised clinical teams can confirm whether a particular study is appropriate.
Frequently asked questions
How much did cancer trials save the State?
A sample of 38 cancer clinical trials saved approximately €6.5 million in treatment costs over the 12 months to August 31st, 2026.
How many patients accessed the trials in the sample?
The 38 trials were accessed by 230 patients.
How many people took part in cancer trials overall?
There were 3,938 cancer-trial participants during the reporting period, including 423 people on drug trials.
Can every cancer patient join a clinical trial?
No. Eligibility depends on the requirements of each study and a patient’s medical circumstances. The treating team can explain whether an appropriate trial is available.
Conclusion
This Breaking News Ireland update highlights the dual value of cancer clinical trials: they can give eligible patients access to carefully monitored treatments while supporting research investment and reducing certain public treatment costs. The latest figures underline why clinical research remains an important part of Ireland’s health system and future cancer strategy.